Why Is BioNTech Stock Gaining Monday?
BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer over standard docetaxel.
Stocks · News reference
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioNTech And OncoC4's Gotistobart Shows Hazard Ratio Of 0.56 Versus Docetaxel In PRESERVE-003 Phase 3 Trial For Previously Treated Squamous Non-Small Cell Lung Cancer
Why Pfizer Stock Was so Healthy in August
Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.
Top 3 Health Care Stocks That May Keep You Up At Night This Month
Thermo Fisher, Moderna and Agilent show overbought RSI readings above 70, warning momentum-focused investors of potential near-term weakness.
Moderna shares are trading higher. The company announced three abstracts on its mRNA-based individualized neoantigen therapy intismeran autogene have been accepted for presentation at the ESMO Congress 2026.